United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
569.11
+2.12 (0.37%)
Apr 28, 2026, 4:00 PM EDT - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 567.57, with a low estimate of 330 and a high estimate of 705. The average target predicts a decrease of -0.27% from the current stock price of 569.11.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $471 → $519 | Hold | Maintains | $471 → $519 | -8.80% | Apr 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $600 → $660 | Strong Buy | Maintains | $600 → $660 | +15.97% | Mar 31, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $486 → $575 | Hold | Maintains | $486 → $575 | +1.03% | Mar 31, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $569 → $626 | Hold | Maintains | $569 → $626 | +10.00% | Mar 31, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $575 → $660 | Strong Buy | Maintains | $575 → $660 | +15.97% | Mar 30, 2026 |
Financial Forecast
Revenue This Year
3.39B
from 3.18B
Increased by 6.39%
Revenue Next Year
3.87B
from 3.39B
Increased by 14.18%
EPS This Year
29.23
from 27.86
Increased by 4.91%
EPS Next Year
34.51
from 29.23
Increased by 18.08%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.7B | 4.5B | ||||||
| Avg | 3.4B | 3.9B | ||||||
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.2% | 34.1% | ||||||
| Avg | 6.4% | 14.2% | ||||||
| Low | -5.2% | -5.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 36.23 | 41.78 | ||||||
| Avg | 29.23 | 34.51 | ||||||
| Low | 24.93 | 22.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 30.0% | 42.9% | ||||||
| Avg | 4.9% | 18.1% | ||||||
| Low | -10.5% | -22.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.